Go Pro
→ Forget the million-dollar nest egg — you only need THIS much (From Investors Alley) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$510.04
$515.31
$339.31
▼
$615.00
$11.78B-1.01382,640 shs347,529 shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$34.26
$34.33
$22.96
▼
$43.15
$4.00B0.691.93 million shs1.40 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.00%+9.14%-4.97%+2.62%+47.53%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
0.00%+7.94%-11.84%+8.01%-9.58%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$510.04
$515.31
$339.31
▼
$615.00
$11.78B-1.01382,640 shs347,529 shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$34.26
$34.33
$22.96
▼
$43.15
$4.00B0.691.93 million shs1.40 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.00%+9.14%-4.97%+2.62%+47.53%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
0.00%+7.94%-11.84%+8.01%-9.58%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2.78
Moderate Buy$689.9335.27% Upside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
2.67
Moderate Buy$97.88185.68% Upside

Current Analyst Ratings Breakdown

Latest VKTX and MDGL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/4/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$605.00
8/3/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$964.00 ➝ $962.00
7/31/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/31/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/31/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$964.00 ➝ $962.00
7/30/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$107.00 ➝ $114.00
7/29/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$578.00 ➝ $587.00
7/27/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$685.00
7/27/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$685.00
7/20/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
7/17/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$958.40M12.29N/AN/A$26.54 per share19.22
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$5.65 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$288.28M-$12.89N/A91.90N/A-25.32%-56.65%-25.53%N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$359.64M-$4.66N/AN/AN/AN/A-94.56%-82.75%10/28/2026 (Estimated)

Latest VKTX and MDGL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2026Q2 2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$2.68-$1.99+$0.69-$1.99$352.13 million$364.25 million
7/29/2026Q2 2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$1.21-$1.10+$0.11-$1.10N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.65
3.20
2.94
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
4.72
4.72

Institutional Ownership

CompanyInstitutional Ownership
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
98.50%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%

Insider Ownership

CompanyInsider Ownership
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
17.60%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
5.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
9023.10 million19.04 millionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
20116.65 million110.47 millionOptionable

Recent News About These Companies

Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?
August 8 at 3:30 PM  |  fool.comhttps://www.fool.com/investing/2026/08/08/better-glp-1-stock-to-buy-eli-lilly-or-viking-ther/
Royal Bank of Canada Decreases Stock Position in Viking Therapeutics, Inc. $VKTX
August 8 at 5:03 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-royal-bank-of-canada-decreases-stock-position-in-viking-therapeutics-inc-vktx-2026-08-08/
Viking Therapeutics, Inc. $VKTX Stake Raised by Dimensional Fund Advisors LP
August 8 at 3:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-viking-therapeutics-inc-vktx-stake-raised-by-dimensional-fund-advisors-lp-2026-08-08/
Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished
August 6, 2026  |  fool.comhttps://www.fool.com/investing/2026/08/06/viking-therapeutics-declined-in-july-and-why-its-l/
First Trust Advisors LP Acquires Shares of 105,570 Viking Therapeutics, Inc. $VKTX
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-first-trust-advisors-lp-acquires-shares-of-105570-viking-therapeutics-inc-vktx-2026-08-06/
Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Recommendation of "Moderate Buy" by Brokerages
August 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30943636
Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/viking-therapeutics-inc-nasdaqvktx-given-consensus-recommendation-of-moderate-buy-by-brokerages-2026-08-06/
The Bull Case For Viking Therapeutics (VKTX) Could Change Following New Obesity Dosing Ambitions And Fresh Financing – Learn Why
August 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/bull-case-viking-therapeutics-vktx-063226172.html
Viking Therapeutics (VKTX) Draws Fresh VK2735 Attention, Is It Still Below Fair Value?
August 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/viking-therapeutics-vktx-draws-fresh-101434034.html
Viking Therapeutics' VK2735 Drives Substantial Optionality, Oppenheimer Says
August 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/viking-therapeutics-apos-vk2735-drives-164415020.html
Research Analysts Offer Predictions for VKTX Q3 Earnings
August 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30937164
Q3 EPS Estimate for Viking Therapeutics Lifted by Analyst
August 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/q3-eps-estimate-for-viking-therapeutics-lifted-by-analyst-2026-08-03/
Viking Therapeutics (VKTX) Receives a Buy from Jefferies
August 2, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VKTX/pressreleases/3578303/viking-therapeutics-vktx-receives-a-buy-from-jefferies/
Viking Therapeutics: Why This Clinical-Stage, Licensed-Technology Play Is a Highly Speculative Bet for Equity Investors
August 2, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VKTX/pressreleases/3590235/viking-therapeutics-why-this-clinical-stage-licensed-technology-play-is-a-highly-speculative-bet-for-equity-investors/
Canaccord Genuity Group Forecasts Strong Price Appreciation for Viking Therapeutics (NASDAQ:VKTX) Stock
August 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30934572
Viking Therapeutics stock moves lower: What's going on?
July 31, 2026  |  msn.comhttps://www.msn.com/en-us/money/news/viking-therapeutics-stock-moves-lower-what-s-going-on/ar-AA295njv
Viking Therapeutics' Q2 Net Loss Widens
July 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/viking-therapeutics-apos-q2-net-082339456.html
VKTX Q2 Earnings Beat Estimates Despite Surge in R&D Costs
July 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vktx-q2-earnings-beat-estimates-163500252.html
VKTX Launches $500M Shelf After Full Enrollment Of Phase 3 Obesity Drug Study – Retail Bets On ‘Exceptionally Great Data’
July 30, 2026  |  stocktwits.comS
VKTX Q2 Earnings Beat Estimates Despite Surge in R&D Costs
July 30, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2964950/vktx-q2-earnings-beat-estimates-despite-surge-in-r-d-costs?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2964950
VKTX stock lags GLP-1 peers in July — but Viking CEO says its obesity drug could offer what rivals can't
July 30, 2026  |  msn.comhttps://www.msn.com/en-in/health/other/vktx-stock-lags-glp-1-peers-in-july-but-viking-ceo-says-its-obesity-drug-could-offer-what-rivals-can-t/ar-AA2924sD

New MarketBeat Followers Over Time

Media Sentiment Over Time

Madrigal Pharmaceuticals stock logo

Madrigal Pharmaceuticals NASDAQ:MDGL

$510.04 0.00 (0.00%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$512.55 +2.51 (+0.49%)
As of 08:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$34.26 0.00 (0.00%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$34.03 -0.23 (-0.67%)
As of 08:51 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas